LOS ANGELES, CA--(Marketwire -02/28/12)- Shares of AMPIO Pharmaceuticals (NASDAQ: AMPE - News) rose just over 5% on nearly three times the average daily volume on Monday as word began to spread that 2012 is a year filled with catalysts for the Colorado based firm. Earlier in the year, AMPE shares traded as high as $9.27 after investors first learned about the company's novel approach to introducing drugs with huge unmet needs -- each with multi-billion dollar markets -- more efficiently and cost effectively than traditional biotechs.
In an exclusive video interview, Michael Macaluso, the founder and Chief Executive Officer of AMPIO Pharmaceuticals tells investors that if 2011 was the firm's year to get their drug candidates into clinical trials, then 2012 will be the year to prove that they really work.
"We expect very good results and believe they will be the stepping stone for this company," explains Macaluso. "We hope to move into the future with a much higher valuation."
During the interview, Macaluso reiterates and clarifies some previous guidance about several key milestones set to occur within the first half of this year and technically it appears that shares may be attempting to recover from their recent bottom level lows. Clinical trial results for one of the company's flagship drugs are expected shortly.
Ampio's product pipeline includes new uses for approved drugs and new molecular entities ('NMEs') for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company's product pipeline includes: Optina™ for diabetic retinopathy, Vasaloc™ for diabetic nephropathy, and Ampion™ for chronic inflammation.
The new video interview with Michael Macaluso is now available at:
In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:
News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556